Molecular Forecaster and TransBIOtech Partner to Accelerate the Discovery of New Small Molecule Therapeutics
BOSTON, USA – MONTREAL AND LÉVIS, CANADA, JUNE 18, 2025 –Molecular Forecaster Inc. (MFI) and TransBIOTech are excited to announce a strategic partnership leveraging the strengths of both organizations to develop drug discovery programs that combine MFI’s custom CADD (computer-aided drug design) solutions with TransBIOTech’s in vitro and in vivo expertise and capabilities.
Both MFI and TransBIOTech focus on accelerating the preclinical stages of the drug design & development process. MFI is a research-as-a-service (RaaS) organization combining human expertise and proprietary technology that integrates chemistry and computational modeling to reduce design cycles in small molecule campaigns. TransBIOTech is a collegial research centre affiliated with Cégep de Lévis. TransBIOTech offers cutting-edge expertise in cell and molecular biology, pharmacology and analytical chemistry to accelerate the path to the clinic of new therapeutic candidates through customized preclinical efficacy and safety studies.
The partnership between the organizations strengthens the synergies between computational and preclinical research, facilitating the transition from in silico prediction to in vitro and in vivo validation. Through this collaboration, TransBIOTech is now able to offer integrated, custom computer-aided design solutions that combine MFI’s silico prediction with TransBIOTech’s tailored experimental validation. MFI’s customers and partners gain direct access to preclinical research laboratories and expert guidance in candidate optimization, enabling rapid validation and de-risking of predicted molecules prior to the GLP certification stage.
“This is a critical time to be focused on strengthening life sciences ecosystems here in Quebec, across Canada, and in jurisdictions around the world,” says Joshua Pottel, Founder and CEO of Molecular Forecaster. “At MFI, we choose to partner with organizations that create opportunities for our clients and the marketplace. Our relationship with TransBIOTech creates a strong bridge between computational and experimental expertise that will enable our clients to link results from computational modeling to tangible experimental data with speed and efficiency.”
“By partnering with Molecular Forecaster, we are enhancing our support for companies developing new drug candidates,” adds Delphine Davan, Head of Partnerships & Business Development for TransBIOTech. “This strategic collaboration will enable us to offer a complete and integrated chain of expertise from molecular modeling to preclinical validation.”
Representatives from MFI and TransBIOTech are attending the BIO International Convention in Boston, June 16-19. You can schedule a discussion by emailing MFI at info@molecularforecaster.com or TransBIOTech at info@tbt.qc.ca.
-//-
About Molecular Forecaster Inc.
Molecular Forecaster Inc (MFI) helps companies make smarter drug design decisions. For six years, we’ve been democratizing computer-aided drug design through our highly collaborative Research-as-a-Service model. Today, we’re integrating what we’ve learned into new and improved software tools. Our goal? To become the go-to partner for small molecule drug design, combining proprietary tools and technologies, our expertise and know-how, and our holistic approach to collaboration that sets our partners up for success. Learn more at molecularforecaster.com
Contact: Josh Pottel, CEO
josh.pottel@molecularforecaster.com
About TransBIOTech
TransBIOTech, a Centre collégial de transfert de technologie (CCTT) affiliated with Cégep de Lévis, QC, Canada, is a research centre and not-for-profit organization specializing in biotechnology. Since 1999, TransBIOTech has provided expert support in drug development, offering customized services in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics and toxicology. TransBIOTech researchers use their expertise and advanced methodologies to evaluate the mechanism of action, efficacy and safety of therapeutic molecules at different stages of preclinical development. For further information: www.transbio.tech
Contact: Delphine Davan, Head of Partnerships & Business Development